1 |
Gulder, T. A., Moor, B. S. 2009. Chasing the treasures of the sea-bacterial marine natural products. Curr. Opin. Microbiol. 12, 252-260.
DOI
|
2 |
Taga, N. 1968. Some ecological aspects of marine bacteria in the KuroShio current. Bul. Misaki Mar. Biol. Inst. Kyoto Univ. 12, 65-76.
|
3 |
Clinical Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard eighth edition (CLSI Document M07-A8). Clinical Laboratory Standards Institute, Wayne, NJ, USA, pp 15-41.
|
4 |
Shirling, E. B., Gottlieb, D. 1966. Methods for characterization of Streptomyces species. Int. J. Syst. Bacteriol. 16, 313-340.
DOI
|
5 |
Jones, K. L. 1949. Fresh isolates of actinomycetes in which the presence of sporogenous aerialmycelia is a fluctuating characteristic. J. Bacteriol. 57, 141.
|
6 |
Kelly, K. L., Judd, D. B. 1965. ISCC-NBS color-name charts illustrated with centroid colors. National Bureau of Standards, Washington, DC, USA, pp 20-99.
|
7 |
Christensen, W. B. 1946. Urea decomposition as a means of differentiating Proteus and paracolon cultures from each other and from Salmonella and Shigella types. J. Bacteriol. 52, 461-466.
DOI
|
8 |
Lanyi, B. 1988. Classical and rapid identification methods for medically important bacteria. Methods Microbiol. 19, 1-67.
DOI
|
9 |
MacFaddin, J. F. 2000. Biochemical tests for identification of medical bacteria. (3rd eds.), Lippincott Williams & Wilkins, Baltimore, USA, pp 20-928.
|
10 |
Siddharth, S., Rai, V. R. 2019. Isolation and characterization of bioactive compounds with antibacterial, antioxidant and enzyme inhibitory activities from marine-derived rare actinobacteria. Nocardiopsis sp. SCA21. Microb. Pathog. 137, 103775.
|
11 |
Liu, L. L., Xu, Y., Han, Z., Li, Y. X., Lu, L., Lai, P. Y. 2012. Four new antibacterial xanthon es from the marine-derived actinomycetes Streptomyces caelestis. Mar. Drugs 10, 2571-2583.
DOI
|
12 |
Haste, N. M., Thienphrapa, W., Tran, D. N., Loesgen, S., Sun, P., Nam, S. J. 2012. Activity of the thiopeptide antibiotic nosiheptide agains t contemporary strains of methicillin-resistant Staphylococcus aureus. J. Antibiot. 65, 593-598.
DOI
|
13 |
Shiota, S. Shimizu, M., Sugiyam, J., Morita, Y., Mizushima. T., Tsuchiya, T. 2004. Mechanisms of action of corilagin and tellimagrandin I that remarkably potentiate the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. Microbiol. Immunol. 48, 67-73.
DOI
|
14 |
Cha, J. D., Lee, J. H., Choi, K. M., Choi, S. M., Park, J. H. 2014. Synergistic effect between cryptotanshinone and antibiotics against clinic methicillin and vancomycin-resistant Staphylococcus aureus. Evid.-based Complement Altern. 450572.
|
15 |
Munita, J. M., Arias, C. A. 2016. Mechanisms of antibiotic resistance. Microbiol. Spectr. 4, doi: 10.1128/microbiolspec.VMBF-0016-2015.
DOI
|
16 |
Davis, S. L., Perri, M. B., Donabedian, S. M., Manierski, C., Robinson-Dunn, S., Hayden, M. K., Zervos, M. J. 2007. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol. 45, 1705-1711.
DOI
|
17 |
Cecchini, M., Langer, J., Slawomirski, L. 2015. Antimicrobial resistance in G7 countries and beyond: economic issues, policies and options for action. Organization for Economic Co-operation and Development (OECD), Paris, France, pp13-18.
|
18 |
Christopher, G. D., Coffey, T. J., Spratt, B. G. 1994. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to β-lactam antibiotics. Trends Microbiol. 2, 361-366.
DOI
|
19 |
Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7, 178-182.
DOI
|
20 |
Bassetti, M., Nicco, E., Mikulska, M. 2009. Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int. J. Am. Agents. 34, S15-S19.
|
21 |
Aitken, M. 2015. Global medicines use in 2020. IMS Institute for Healthcare Informatics, NJ, USA, pp 3-8.
|
22 |
Kemung, H. M., Tan, L. T. H., Khan, T. M., Chan, K. G., Pusparajah, P., Goh, B. H., Lee, L. H. 2018. Streptomyces as a prominent resource of future anti-MRSA drugs. Frontiers Microbiol. 9, 1-26.
DOI
|
23 |
Proksch, P., Edrada, R. A., Ebel, R. 2003. Drugs from the sea- opportunities and obstacles. Mar. Drugs. 1, 5-17.
DOI
|
24 |
Jose, P. A., Jebakumar, R. S. D. 2014. Unexplored hypersaline habitats are sources of novel actinomycetes. Front Microbiol. 5, 242.
|